Valopicitabine

Cat. No.:	HY-108060
CAS No.:	640281-90-9
Molecular Formula:	$C_{15}H_{24}N_4O_6$
Molecular Weight:	356.37
Target:	HCV; HCV Protease; Nucleoside Antimetabolite/Analog
Pathway:	Anti-infection; Metabolic Enzyme/Protease; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination[1][2].
IC_{50} & Target	HCV[1]
In Vivo	Valopicitabine (NM283) (100 mg/kg; oral administration; Sprague-Dawley Rats) shows the C_{max}, AUC, $t_{1/2}$, and t_{max} were 3.624 μg/mL, 8.95 μg h/mL, 0.64 hours and 1 hour, respectively[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pierra C, et al. Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):767-70.

[2]. Pierra C, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J Med Chem. 2006 Nov 2;49(22):6614-20.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA